Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Payables (2020 - 2025)

Caribou Biosciences has reported Payables over the past 6 years, most recently at $5.8 million for Q4 2025.

  • Quarterly Payables rose 133.56% to $5.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Dec 2025, up 133.56% year-over-year, with the annual reading at $5.8 million for FY2025, 133.56% up from the prior year.
  • Payables was $5.8 million for Q4 2025 at Caribou Biosciences, up from $3.8 million in the prior quarter.
  • Over five years, Payables peaked at $5.9 million in Q1 2024 and troughed at $426000.0 in Q2 2022.
  • The 5-year median for Payables is $3.2 million (2024), against an average of $3.1 million.
  • Year-over-year, Payables crashed 89.43% in 2022 and then soared 940.61% in 2023.
  • A 5-year view of Payables shows it stood at $4.0 million in 2021, then crashed by 71.28% to $1.1 million in 2022, then skyrocketed by 172.25% to $3.1 million in 2023, then dropped by 20.64% to $2.5 million in 2024, then soared by 133.56% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Payables are $5.8 million (Q4 2025), $3.8 million (Q3 2025), and $3.2 million (Q2 2025).